Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1.
Sign Up to like & getrecommendations! Published in 2019 at "Drug and chemical toxicology"
DOI: 10.1080/01480545.2019.1679828
Abstract: Nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) is an emerging therapeutic target for a spectrum of human diseases. NX-13 is a small molecule therapeutic designed to target and activate NLRX1 to induce immunometabolic… read more here.
Keywords: exploratory studies; toxicity pharmacokinetics; pharmacokinetics rodents; toxicity ... See more keywords